Skip to main content
SpringerLink
Log in

Rituximab, ofatumumab boxed warning of HBV reactivation risk

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • FDA. Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). Internet Document : [4 pages], 25 Sep 2013. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rituximab, ofatumumab boxed warning of HBV reactivation risk. Reactions Weekly 1472, 3 (2013). https://doi.org/10.1007/s40278-013-6226-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-013-6226-4

Search

Navigation